Estrella Immunopharma develops transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives.
Estrella Immunopharma has raised $8.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
Estrella Immunopharma is headquartered in Emeryville, United States.
Estrella Immunopharma develops transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives.
Estrella Immunopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Estrella Immunopharma — Funding & Investors." VCBacked, January 5, 2026, https://www.vcbacked.co/company/estrella-immunopharma. Accessed August 15, 2026.
VCBacked. (2026). Estrella Immunopharma — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/estrella-immunopharma
{{cite web |title=Estrella Immunopharma — Funding & Investors |url=https://www.vcbacked.co/company/estrella-immunopharma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated